~~<i id='41777F54FD'><strike id='41777F54FD'><tt id='41777F54FD'><pre id='41777F54FD'></pre></tt></strike></i>~~

Home» leisure time» knowledge

knowledge

author：focus 2025-10-06 13:25:59 Page View：9

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Congress: Prevent baby formula shortages by passing a new bill
Next article： Activists slam private health insurers over coverage restrictions

comprehensive

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

KristofferTripplaar/SipaviaAPTheFoodandDrugAdministrationgrantedconditionalapprovalThursdaytothefirs

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Congress: Prevent baby formula shortages by passing a new bill

ScottOlson/GettyImagesFamiliesinAmericashouldneverhavetoscroungeforbabyformula.TheUnitedStatesneedsa